Posted in | News | Nanomedicine | Nanobusiness

Platypus Technologies Awarded Phase I SBIR Grant from NIH

Platypus Technologies, developer of develops innovative products for the analytical and life sciences that utilize recent advances in nanotechnology and materials science, announces that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant for $100,000 from the National Institutes of Health.

This 1-year funded project will enable the Company to further expand its cell motility assay product line into the High Througput Screening (HTS) market. By implementing modifications to Platypus' current Oris™ 96-well cell migration assay, the Company aims to make the proposed assay compatible with automated liquid handling systems and High Content Imaging (HCI) platforms.

According to Renee Herber, Program Manager, “This is an exciting project that will dramatically improve testing throughput and efficiency, while reducing the cost per assay for researchers.” Platypus Technologies has received over $18 million in federal funding to develop cell-based assays for the study of cell motility, and LC-based nanotechnology products for environmental monitoring, infectious disease testing and homeland security.

Platypus Technologies, LLC develops innovative products for the analytical and life sciences that utilize recent advances in nanotechnology and materials science. Platypus Technologies has successfully launched several products in the Oris™ cell-based assay line that enable life science researchers to study cell migration; a process critical to a variety of in vivo processes. The Company is also developing a range of products, for diagnostic, environmental and laboratory applications, that derive from a proprietary platform technology utilizing liquid crystals for the rapid and low-cost detection of molecular interactions.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.